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OBJECTIVES We evaluated whether the angiotensin II (Ang II) receptors from perioperation through
one-year post-transplantation predict the transplant coronary artery disease (TCAD) pro-
gression.
BACKGROUND The role of Ang II receptors (type 1: AT1R; type 2: AT2R) in TCAD is uncertain.
METHODS We investigated 28 heart donors and the corresponding recipients. The levels of AT1R and
AT2R messenger ribonucleic acid (mRNA) were examined in lymphocytes from the donor
spleen and in the donor heart at one-week and one-year posttransplantation to determine
their association with the progression of TCAD, measured as changes in maximal intimal
thickness (CMIT) and plaque volume (CPV) by intravascular ultrasound (IVUS) examina-
tions.
RESULTS The AT1R mRNA in lymphocytes from the donor spleen (CMIT: r  0.73, p  0.0001;
CPV: r  0.69, p  0.0001) and in the donor hearts at one-week (CMIT: r  0.52, p 
0.005; CPV: r  0.56, p  0.002) and at one-year (CMIT: r  0.63, p  0.0001; CPV:
r  0.43, p  0.004) post-transplantation along with AT2R mRNA in the donor hearts at
one-year post-transplantation (CMIT: r 0.3, p 0.0001; CPV: r 0.53, p 0.009) were
univariate predictors, whereas AT1R mRNA in lymphocytes and in the donor hearts at
one-year post-transplantation proved to be multivariate predictors of the progression of
TCAD.
CONCLUSIONS These data suggest a role for Ang II receptors in the pathogenesis of TCAD and support a
novel concept that TCAD may have its origin in the donor per se and may be modulated by
the recipient’s inherent biological factors. (J Am Coll Cardiol 2004;43:1565–73) © 2004 by
the American College of Cardiology FoundationA
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lransplant coronary artery disease (TCAD) is a disease of
he vasculature of the donor heart in a recipient (1) and
nvolves both intramyocardial and epicardial branches of the
ransplant coronary arteries (2). Whereas coronary angiog-
aphy demonstrates TCAD in 10% to 20% of heart trans-
lant recipients (3), intravascular ultrasound (IVUS) iden-
ifies abnormal intimal thickness in 50% of heart transplant
ecipients at one-year post-transplant (4). Also, TCAD is a
ajor cause of morbidity and mortality in those surviving
ast the first year following cardiac transplantation (5).
lthough immune mechanism has been implicated in its
athogenesis (6), the exact molecular mechanisms underly-
ng the progression of TCAD are uncertain.
Recent investigations have elucidated the role of the
enin-angiotensin system (RAS) in the pathobiology of
ative coronary artery disease (7). The biological effects of
ngiotensin II (Ang II) are mediated through two major
ubtypes of receptors—Ang II type 1 receptor (AT1R) and
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ailure, The Cleveland Clinic Foundation, Cleveland, Ohio. A portion of the data in
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harmacology, and Pathology of the American College of Cardiology, March 2003,
hicago, Illinois. This study was supported by a grant from AstraZeneca.
Manuscript received September 9, 2003; revised manuscript received November 24,t003, accepted November 25, 2003.ng II type 2 receptor (AT2R). The role of Ang II receptors
n the pathogenesis of TCAD is not known. Because
CAD involves the donor heart artery, we attempted to
nvestigate Ang II receptor expression in the donor before
ardiac procurement and subsequently in the transplanted
eart. We hypothesized that Ang II receptor expression is
ncreased in the donor before donor heart procurement,
hich may contribute to the development of TCAD in a
ecipient. We assessed AT1R and AT2R in lymphocytes
erived from the donor spleen obtained before transplanta-
ion and in donor heart at one-week and one-year post-
ransplantation. We performed paired-IVUS examinations
o estimate the progression of TCAD and serial endomyo-
ardial biopsies to assess heart rejection. The purpose of
hese experiments was to determine whether: 1) the possible
lterations in Ang II receptors in the donor before trans-
lantation persists in the donor heart after transplantation,
nd 2) whether such alterations relate to subsequent devel-
pment of transplant vasculopathy.
ETHODS
tudy population. We investigated 28 heart donors and
he corresponding recipients. The lymphocytes were iso-
ated from the donor spleen. Recipients of heart transplan-
ation had serial surveillance endomyocardial biopsies
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Angiotensin II Receptors and Transplant Vasculopathy May 5, 2004:1565–73hrough the first-year post-transplantation. Endomyocar-
ial biopsies obtained at one week and at one year after
ransplantation were used to determine the expression of
T1R and AT2R messenger ribonucleic acid (mRNA).
aseline (within four weeks’ post-transplantation) and one-
ear follow-up IVUS examinations were performed to
easure the progression of TCAD. The protocol was
pproved by the ethics review committee of our institution.
tudy end points. The prespecified end points were: 1)
xpression of AT1R and AT2R mRNA in lymphocytes and
n donor hearts at one week and one year following
ransplantation, 2) average biopsy score of the transplanted
eart, and 3) changes in maximal intimal thickness (CMIT)
nd in plaque volume in transplant coronary arteries over
ne year.
xperimental protocol. ISOLATION OF LYMPHOCYTES
ROM DONOR SPLEEN. Donor spleen was injected with
ank’s balanced salt solution (HBSS) and the discharge
ontaining cells collected and centrifuged. Cells at interface
ere transferred to conical tubes, diluted with HBSS, and
entrifuged. The cell pellet was resuspended in fresh HBSS
nd centrifuged. Cells were then mixed with Lympho-Kwik
/B, incubated at 37°C for 20 min, diluted with fresh
BSS, and centrifuged. Finally, the lymphocyte pellet was
ashed by HBSS and resuspended in 0.5% bovine serum
lbumin (8).
NDOMYOCARDIAL BIOPSY. Right ventricular endomyocar-
ial biopsies were obtained using the standard transjugular
pproach. Endomyocardial tissues were divided into parallel
arts for histological analysis and ribonucleic acid (RNA)
solation. Specimens for histological analysis were fixed in
ormalin, routinely processed, and embedded in paraffin.
ections were stained with hematoxylin-eosin to determine
he grade of cellular rejection in accordance with the criteria
stablished by the Working Formulation of the Interna-
ional Society for Heart and Lung Transplantation (9).
ecipients of heart transplantation had approximately 13
ndomyocardial biopsies through the first year of post-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
Ang II  angiotensin II
AT1R  angiotensin II type 1 receptor
AT2R  angiotensin II type 2 receptor
CMIT  changes in maximal intimal thickness
CPV  changes in plaque volume
HBSS  Hank’s balanced salt solution
IVUS  intravascular ultrasound
mRNA  messenger ribonucleic acid
RAS  renin-angiotensin system
RNA  ribonucleic acid
RT-PCR  reverse transcription-polymerase chain
reaction
TCAD  transplant coronary artery disease
vWF  von Willebrand factorransplantation. Each biopsy was allocated a score (1–6) pepending on the degree of cellular rejection. Average
iopsy score was determined as the sum of individual scores
ivided by the number of biopsies. Patients were classified
nto low (biopsy score 1.0), intermediate (biopsy score
.0–1.5), and high (biopsy score 1.5) biopsy score cate-
ories.
SOLATION OF TOTAL RNA. Total RNA from lymphocytes:
mbion RNAqueous TM-4PCR kit (Ambion, Austin,
exas) was used to isolate total RNA from lymphocytes
erived from donor spleen. The lymphocytes were treated
ith lyses solution and 64% isoamyl alcohol and then
pplied to filter cartridge placed into a collecting tube. After
entrifugation, the flow-through was discarded. Preheated
lution solution was applied to the filter and then centri-
uged for 30 s to recover the eluate containing total RNA.
Total RNA from endomyocardial biopsies: Biopsy specimens
ere retrieved from frozen blocks and were rapidly pro-
essed to isolate total RNA using the Totally RNA kit
Ambion) following the manufacturer’s instructions. Briefly,
issue was homogenized in 200 l of denaturation solution.
n equal volume of phenol:chloroform was added, vortexed,
nd then stored on ice for 5 min. After centrifugation, the
queous phase was transferred to a new tube, and 1/10
olume of sodium acetate solution was added. Next, acid:
hloroform was added, vortexed, and stored on ice for 5 min
efore centrifugation. The upper aqueous phase was trans-
erred to a new tube, precipitated with isopropanol, and
tored at 20°C for 30 min before centrifugation. The
ellet was washed with 70% ethanol and resuspended in
iethyl pyrocarbonate-treated distilled water.
Assessment of RNA yield: The concentration and purity of
NA was determined by its absorbency in a spectropho-
ometer. The yield of total RNA was 400 to 800 ng per
pecimen. Therefore, only during initial experiments, a
ortion of recovered total RNA was electrophoresed to
etermine its purity.
EVERSE TRANSCRIPTION. The RNA samples were
everse-transcribed using TaqMan reverse transcription kit
Applied Biosystems, Foster City, California). The mix was
liquoted in individual tubes, and template RNA was added.
amples were incubated for 90 min at 25°C, 45 min at 48°C,
nd 5 min at 95°C. A tube with no reverse transcriptase was
ncluded to control for deoxynucleic acid contamination.
EAL-TIME REVERSE TRANSCRIPTION–POLYMERASE CHAIN
EACTION (RT-PCR). Both AT1R and AT2R primers and
robes for RT-PCR were designed using the PRIMER
xpress program. The BLASTN search was conducted
GenBank, EMBL) to confirm the gene specificity and
bsence of DNA polymorphism. The oligonucleotide se-
uences of TaqMan probe and primers were as follows:
T1R—TaqMan probe FAM-1422 ATCCACCAA-
AAGCCTGCACACCATGTTT-TAMRA, forward
rimer 1350 AGCCAAATCCCACTCAAACCT, reverse
rimer 1470 TCGAACATGTCACTCAACCTCA;
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ATTTGGTGCCTTCC-TAMRA; forward primer 919
AGTCCTGAAGATGGCAGCTG; reverse primer
055 CAGGTCAATGACTGCTATAACTTCG.
To measure gene expression, a reaction mix was prepared
n ice with TaqMan buffer, MgCl2, dATP, dCTP, dGTP,
UTP; AmpErase UNG, and AmpliTaq Gold DNA poly-
erase, 18S ribosome forward and reverse primers and
robe (50 nM), AT1R or AT2R forward and reverse primers
nd probes (100 nM). The RT-PCR reaction was per-
ormed in a final volume of 50 l in duplicate using ABI
rism 7700 (Applied Biosystems). Each RT-PCR run
ncluded a no-template control, the calibration, and pa-
ient’s complementary deoxyribonucleic acid. The thermal
ycling conditions comprised an initial denaturation at 50°C
or 2 min and 95°C for 10 min followed by 40 cycles of
enaturation at 95°C for 15 s, and annealing and extension
t 62°C for 1 min. Data were analyzed by the Sequence
etector Version 1.5 (Applied Biosystems). Using the
 CT method of relative quantification, we reported the
old change in gene expression (10).
MMUNOFLUORESCENCE STUDIES. Paraffin section prepara-
ion: Immunofluorescence labeling for AT1R and von Wil-
ebrand factor (vWF) were performed on 5-m-thick
ormalin-fixed and paraffin-embedded sections. Paraffin
ections were dewaxed with xylene and hydrated with
ecreasing concentrations of ethanol. The sections were
ashed in 0.01 mol/l phosphate buffered saline (0.01 mol/l
BS, pH 7.4) and incubated in 2% bovine serum albumin
or 30 min at 37°C to eliminate nonspecific staining.
Immunofluorescence stain for AT1R: The above sections
ere incubated with antibody to AT1R (chicken polyclonal
ntibodies to rat AT1R, Jackson Immuno Research Labo-
atories, West Grove, Pennsylvania) in 1:100 dilutions for
h at room temperature and additional 24 h at 4°C. The
lides were then washed and incubated with FITC-
onjugated anti-chicken secondary antibody (Jackson Im-
uno Research Laboratories).
Immunofluorescence stain for vWF: To identify the vascular
ndothelium within the endomyocardial biopsy section,
mmunofluorescence stain for vWF was performed. The
ections were incubated with mouse monoclonal antibody to
WF (Dako, Carpinteria, California) in 1:100 dilutions for
h at room temperature and an additional 24 h at 4°C. The
lides were then washed and incubated with rhodamine-
onjugated anti-mice IgG secondary antibody (Jackson
mmuno Research Laboratories).
Dual immunofluorescence staining for AT1R and vWF: The
ual labeling was performed by sequential treatment of
ndomyocardial biopsy sections by primary antibodies to
T1R and vWF and their respective secondary antibodies as
escribed above.
Image analysis: Sections were examined by LEICA DMR
mmunofluorescence microscope (Heidelberg, Germany) and
mages were captured using the Micromacs digital camera yPrinceton Instruments, Trenton, New Jersey) and Image-Pro
lus software (Mediacybernautics, Silver Spring, Maryland).
VUS. The technique of IVUS was earlier reported in
etail (11). Briefly, using standard technique for intracoro-
ary catheter delivery, the operator advances the imaging
evice into the coronary artery to the most distal position
hat could be safely reached and then retracts at a constant
peed using an automated pull-back system while recording
erial cross-sectional images on a super-VHS tape. Proxi-
al, mid, and distal segments of the three major epicardial
oronary arteries, defined according to Coronary Artery
urgery Study classification, were targeted for imaging (12).
atched sites were analyzed at baseline and at one year after
ransplantation to assess: 1) change in maximal intimal
hickness (CMIT), and 2) change in plaque volume (CPV).
he threshold to define transplant vasculopathy was a
MIT 0.3 mm over one year (11).
ata analysis. Shape of the distribution curve of the
ndividual variables was determined from Z-score histo-
rams, which show variability among measurements. In
ormal distribution, 2.5% of the observations will be below
he mean minus 2 SDs. Data were expressed as mean with
D when the variables showed a normal distribution. Data
hat did not follow the normal distribution were expressed
s median and interquartile range (25th to 75th percentile).
he Pearson correlation was used to express relationships.
nivariate models were constructed to determine the associa-
ion of gene expression and progression of TCAD and mul-
ivariate regression models to identify the relative predictive
ower of gene expression. The order of incorporation of
o-variates in multiple regression models was lymphocyte
T1R, donor heart AT1R at one week and one year after
ransplantation, and donor heart AT2R at one year following
ransplantation. The Student t test was used to compare
ubgroups when the variables were normally distributed. The
ann-Whitney test was used to compare groups when the
ariables were skewed, such as levels of AT1R and AT2R. The
ruskal-Wallis test was used to compare three subgroups
ccording to average biopsy score, where the numbers of
atients were unequal and variables were skewed in
istribution.
Categorical variables were compared by the Fisher exact
est, and the strength of association between AT1R in
ymphocytes or in donor hearts at one year after transplan-
ation and the development of transplant vasculopathy was
tudied using receiver operating characteristic curves. The
rea under the curve was estimated using the Hanley and
cNeil method (13). Differences were considered signifi-
ant at p  0.05. Because of small sample size in this
xploratory study, no adjustment for the other confounders
as made and no model-building strategy was adopted.
ESULTS
atients. The mean age of the donors was 35.1  12.9
ears, and for recipients it was 55  11.8 years. There were
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eart failure was ischemic cardiomyopathy in 15 (54%) and
diopathic dilated cardiomyopathy in 13 (46%) patients.
ean ischemic time was 170  53 min. All patients were
n triple immunosuppressive drugs including prednisone,
yclosporine, and mycophenolate mofetil. Eighteen patients
ere on angiotensin I-converting enzyme (ACE) inhibitors
or the treatment of hypertension.
aboratory characteristics. The overall average biopsy
core at one year was 1.25  0.50, CMIT was 0.46  0.37
m, and maximal change in plaque volume was 2.75 1.99
m3. Figure 1 shows IVUS images of a transplant coronary
rtery at baseline and at one-year follow-up. Expression
alues of AT1R mRNA and AT2R mRNA in lymphocytes
erived from donor spleen (9.9, 3.1 to 23.8 fold; 0.32, 0.12
o 1.80 fold), in donor hearts at one week (1.04, 0.6 to 2.0
old; 2.33, 1.23 to 3.84 fold), and at one year (1.5, 0.6 to 3.8
old; 0.55, 0.78 to 1.01 fold) after transplantation were
resented as the median and interquartile range (25th to
5th percentile). Levels of AT1R mRNA in lymphocytes
rom the donor were correlated with those in the donor
eart at one week (r  0.60, p  0.001) and at one-year (r
0.66, p  0.0003) after transplantation in recipients. No
uch relationship was observed for AT2R mRNA. Both
MIT and maximal change in plaque volume (CPV) were
ignificantly correlated with AT1R expression in lympho-
ytes derived from donor spleen (CMIT: r  0.73, R2 
.54, p  0.0001; CPV: r  0.69, R2  0.47, p  0.0001)
nd in donor hearts at one week (CMIT: r  0.52, R2 
.27, p 0.005; CPV: r 0.56, R2 0.32, p 0.002) and
t one year (CMIT: r 0.63, R2 0.40, p 0.0001; CPV:
 0.43, R2  0.18, p  0.004) after transplantation. Only
he level of AT2R mRNA in the donor heart at one year
ollowing transplantation was associated with CMIT (r 
2 2
igure 1. Intravascular ultrasound images of transplant coronary artery dise
.1 mm. (B) Transplant coronary artery at one year showing an intimal th.73, R  0.54, p 0.0001) or CPV (CMIT: r 0.53, R t0.28, p  0.009). Figure 2 displays regression plots
etween AT1R mRNA and CMIT or CPV. No relation-
hip was observed between average biopsy score and CMIT
r  0.05, p  0.74) or CPV (r  0.15, p  0.30).
ultivariate models. We incorporated donor age, AT1R
RNA in donor lymphocytes, and donor heart AT1R
RNA at one week and at one year after transplantation,
nd donor heart AT2R mRNA at one year following
ransplantation in a multivariate regression model. The
T1R mRNA levels in donor lymphocytes (p  0.04) and
n donor heart at one year after transplantation (p  0.01)
ere identified as independent predictors of CMIT, with a
ombined r value of 0.88 and combined R2 of 0.80.
onor characteristic and Ang II receptor gene expression.
onor age was correlated with the CMIT (r  0.39, p 
.03), CPV (r  0.37, p  0.051), and AT1R mRNA in
ymphocytes (r  0.51, p  0.005). The cause of donor
eath was stroke in 11 patients and other traumatic causes in
he remaining 17 subjects.
mmunofluorescence studies. Figure 3 shows endomyo-
ardial biopsy sections labeled for AT1R, vWF, and dual
tain for both from a patient whose transplanted heart
emonstrated increased expression of AT1R mRNA. The
T1R was expressed in vasculature and the surrounding
nterstitial tissue (Fig. 3a). As expected, vWF was localized
o the arteriole (Fig. 3b). Figure 3c confirms colocalization
f AT1R and vWF in the arteriole.
ubgroup analysis. TRANSPLANT VASCULOPATHIC SUB-
ROUPS. Fifteen (54%) heart transplant recipients devel-
ped transplant vasculopathy and were compared to the
emaining 13 (44%) recipients who did not develop
asculopathy. Except for donor age, no differences existed
n recipient age, gender, ischemic time, treatment with
ngiotensin-converting enzyme (ACE) inhibitors, posi-
A) Transplant coronary artery at baseline showing an intimal thickness of
ss of 0.8 mm.ase. (
ickneive cytomegalovirus (CMV) viremia, and rejection score
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etween AT1R mRNA or AT2R mRNA and IVUS
ndices of vasculopathy were adjusted to age. Expression
f AT1R mRNA in lymphocytes derived from the donor
pleen and in the donor hearts at one year after trans-
lantation was significantly higher in the transplant
asculopathic group compared with the nonvasculopathic
roup (Table 1).
UBGROUPS ACCORDING TO AVERAGE BIOPSY SCORE. Eight
eart transplant recipients had low, 8 had intermediate, and
2 had high average biopsy score. No differences in CMIT
0.58  0.50, 0.40  0.39, 0.54  0.37 mm, respectively;
3
igure 2. Regression plots showing relationship between serial angioten
ltrasound indices of transplant coronary artery disease. CMIT  change 0.25), CPV (2.9  2.3, 1.7  1.4, 3.2  2.4 mm , 1espectively; p  0.24), development of transplant vascu-
opathy (5/8, 2/8, 8/12, respectively; p  0.16), or levels of
T1R or AT2R mRNA in lymphocytes and transplanted
earts were observed among these subgroups (Table 2).
UBGROUPS OF HEART TRANSPLANT RECIPIENTS TREA-
ED WITH, AND THOSE NOT TREATED WITH, ACE INHIBI-
ORS. Heart transplant recipients treated with (n 18) and
hose not treated with (n 10) ACE inhibitors were similar
n age, ischemic time, and average biopsy score. No differ-
nces existed in the levels of AT1R mRNA, in lymphocytes
median and interquartile range: 8.5, 3.1 to 35.0 vs. 8.5, 3.2
o 22.0; p  0.3), or in donor heart at one week (0.8, 0.5 to
I type 1 receptor (AT1R) messenger ribonucleic acid and intravascular
aximal intimal thickness.sin I
s in m.6 vs. 1.2, 0.8 to 2.2; p  0.1) and one year (1.0, 0.6 to 2.5
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Angiotensin II Receptors and Transplant Vasculopathy May 5, 2004:1565–73s. 2.5, 0.6 to 3.9; p  0.6) after transplantation in the
ecipients who were treated and those not treated with ACE
nhibitors. Levels of AT2R mRNA in lymphocytes (0.3, 0.1
o 1.4 vs. 0.5, 0.1 to 4.3; p  0.4) and in the donor heart at
ne week (2.3, 0.9 to 3.8 vs. 3.1, 2.1 to 3.9; p  0.3) and at
ne year (0.3, 0.05 to 0.9 vs. 0.8, 0.4 to 1.3; p  0.3) after
igure 3. Immunofluorescence labeling for angiotensin II type 1 receptor
nd von Willebrand factor on sections of the endomyocardial biopsies of
he transplanted heart. (a) Biopsy section showing immunoreactivity for
ngiotensin II type 1 receptor predominantly in vascular and perivascular
nterstitial tissue. (b) Biopsy section demonstrating immunoreactivity for
on Willebrand factor in the endothelium. (c) Biopsy section showing
olocalization of angiotensin II type 1 receptor and von Willebrand factor
n vascular endothelium.ransplantation were similar in these groups. ieceiver operating characteristic curves. The area under
he curve for AT1R mRNA in lymphocytes derived from
onor spleen was 0.82 (66.7% sensitivity, 76.9% specificity,
6.9% positive predictive value, and 66.7% negative predic-
ive value) and for the donor heart AT1R mRNA at one year
fter transplantation was 0.74 (61.5% sensitivity, 81.8%
pecificity, 80.0% positive predictive value, and 64.3% neg-
tive predictive value) when the threshold for defining
asculopathy was a CMIT 0.3 mm.
ISCUSSION
he novel findings of this study are as follows. First, the
T1R mRNA level in lymphocytes from the donor spleen
orrelated with that of the donor heart at one week or at one
ear after transplantation, and these levels were directly
ssociated with the subsequent progression of TCAD.
econd, the upregulation of AT1R mRNA, initially in the
onor before recipient antigen was presented and subse-
uently in the transplanted heart, increased the risk of
ransplant vasculopathy in recipients. Third, the AT1R was
redominantly localized to the vasculature of the trans-
lanted heart in recipients with transplant vasculopathy.
ourth, donor heart AT2R mRNA predicted the progres-
ion of TCAD only late after transplantation. These results
otentially support a role for Ang II receptors in the
athogenesis of TCAD.
Our present investigations support a novel concept that
asculopathy of the donor heart in a transplant recipient
ay have its origin in the donor per se and may be
ubsequently modulated by the recipient’s inherent biolog-
cal factors. This notion has been supported by our earlier
nvestigation, which showed that peri-transplantation isch-
mic injury to the myocardium correlates with the subse-
uent transplant vasculopathy (14). We chose to investigate
ng II receptors in lymphocytes from the donor spleen
ecause donor spleen comprises both resident and circulat-
ng pools of lymphocytes that have a relatively long half-life
nd thus potentially reflect the dramatic perturbations in
ystemic and regional (spleen) hormonal milieu in the donor
rior to organ procurement. Both heart (15) and lympho-
ytes isolated from the spleen (16) are known to express Ang
I receptors. Few experimental and clinical studies support a
ossible role of RAS including Ang II receptors in the
athogenesis of TCAD.
For instance, AT1R blockade in animal models and ACE
nhibition in clinical studies slowed the progression of
oronary intimal thickness after heart transplantation
17,18). Both donor and recipient ACE gene polymorphism
orrelate with increased risk of TCAD after heart trans-
lantation (19,20). However, our observations in this study
howed that the expression of AT1R in the transplanted
eart was independent of treatment with ACE inhibitors.
hese findings may suggest an incomplete inhibition of the
onversion of Ang I to Ang II, activation of ACE-
ndependent pathways for the generation of Ang II, or
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f ACE inhibitors (21). Consistent with these observations,
T1R blockers as add-on treatment to ACE inhibitor-
ontaining-regimen produce additional clinical benefit (22).
hese data support our finding that AT1R expression was
ignificantly correlated with IVUS indices of TCAD re-
ardless of ACE inhibitor treatment.
Transplant coronary artery disease is characterized by
rogressive increase in intimal thickness, especially within
he first year following transplantation (23). The severity of
CAD, measured as intimal thickness by IVUS examina-
ion, is an important marker of prognosis following trans-
lantation (24). Through its direct and immune modulating
ffects, Ang II might play an important role in the patho-
hysiology of TCAD. Ang II promotes cellular growth/
poptosis, fibrosis, inflammation, and extracellular matrix
emodeling, all of which have implications in the pathogen-
sis of vascular disease (25). The vast majority of these
ffects are mediated through AT1Rs (25), the number of
hich may define the biological efficacy of Ang II (26).
An association between cardiac AT2R mRNA and the
evelopment of TCAD in this study raises important and
ntriguing issues. Although the role of AT2R in the cardio-
ascular system is poorly understood, it generally opposes
Table 1. Subgroup Analysis: Transplant Vascu
Variables
Vas
(n
Donor age (yrs) 39
Donor gender (male/female)
Cause of donor death (trauma/other)
Recipient age (yrs) 56
Recipient gender (male/female)
Ischemic time (min) 17
ACE inhibitor (n)
Average biopsy score 1.3
Positive CMV status
Lymphocyte AT1R mRNA 22.0
Donor heart AT1R at 1-wk post-Tx 1.2
Donor heart AT1R at 1-yr post-Tx 2.8
Lymphocyte AT2R 0.20
Donor heart AT2R at 1-wk post-Tx 2.10
Donor heart AT1R at 1-yr post-Tx 0.61
The mRNA expressions of AT1R and AT2R were presented
ACE angiotensin-converting enzyme; AT1R and AT2R
mRNA  messenger ribonucleic acid; post-Tx  posttransp
Table 2. Angiotensin II Receptor Expression i
Variables
Low
(n  8)
AT1R mRNA (fold)
Donor lymphocyte (spleen) 9.9 (4.1–23.4
Donor heart at 1-week post-Tx 1.6 (0.9–1.8)
Donor heart at 1-yr post-Tx 0.7 (0.1–2.6)
AT2R mRNA (fold)
Donor lymphocyte (spleen) 0.4 (0.2–1.2)
Donor heart at 1-week post-Tx 2.3 (0.9–3.5)
Donor heart at 1-yr post-Tx 0.5 (0.1–0.6)
The mRNA expressions of AT1R and AT2R were presented
Abbreviations as in Table 1.he AT1R-mediated effects on the cardiovascular system.
owever, recent reports support a role of AT2R in vascular
emodeling, apoptosis, and cardiac hypertrophy indepen-
ent of its mere antagonistic interaction with AT1R (15,27).
he increase in cardiac AT2R mRNA transcripts with
ncreasing CMIT and plaque volume in transplant coronary
rteries in the present investigation may imply a positive role
f AT2R in the pathogenesis of TCAD or may be an
verexpression to antagonize the biological effects of AT1R.
he role of immune mechanisms in the progression of
CAD is not completely understood. Evidence suggests
hat the incidence of TCAD has, indeed, increased follow-
ng introduction of cyclosporine (28). Moreover, reports
nvestigating an association between allograft rejection and
CAD produced conflicting results (23,29,30). Our find-
ngs support earlier reports suggesting no association be-
ween graft rejection and the development of TCAD
23,29).
Some recent studies suggest that RAS may both stimulate
nd be stimulated by alloimmune responses (31). Immune
ells synthesize Ang II and express Ang II receptors (32,
3). In a cardiac transplant model, Nataraj et al. (16)
lucidated a molecular mechanism for the RAS-mediated
egulation of cellular immune response and suggested that
hy
athy
5)
Nonvasculopathy
(n  13) p Value
2.2 30.4  11.9 0.03
6/7 0.84
10/3 0.13
.9 56.0  12.2 0.91
9/4 0.80
8 164  48 0.50
10 0.75
.57 1.2  0.43 0.45
3 0.67
9.4) 3.5 (2.2–6.9) 0.004
.1) 0.8 (0.5–1.8) 0.35
.9) 0.6 (0.4–1.3) 0.003
1.80) 0.52 (0.30–2.10) 0.22
3.90) 3.10 (1.30–4.30) 0.71
1.40) 0.36 (0.05–0.98) 0.53
edian (25th to 75th interquartile range).
giotensin II type 1 and 2 receptor; CMV cytomegalovirus;
ion; wk  week.
bgroups According to Average Biopsy Score
Intermediate
(n  8)
High
(n  12) p Value
3.7 (2.1–17.5) 16.7 (3.3–28.6) 0.47
0.74 (0.3–1.5) 0.9 (0.5–2.3) 0.27
1.2 (0.6–3.6) 1.2 (0.9–3.6) 0.60
1.4 (0.06–3.7) 0.32 (0.05–1.8) 0.97
2.7 (1.4–3.1) 2.9 (1.3–4.2) 0.78
0.9 (0.2–1.5) 0.3 (0.1–0.9) 0.66
edian (25th to 75th interquartile range).lopat
culop
 1
.8  1
7/8
6/9
.9  9
10/5
7  5
8
3  0
5
(9.3–2
(0.6–2
(1.4–3
(0.02–
(1.20–
(0.21–
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-cell proliferation. Consistent with an interaction between
mmune mechanism and RAS, treatment with immunosup-
ressive drugs, including cyclosporine A, alleviates Ang
I-induced organ damage (34,35). Moreover, AT1R block-
de reduces the risk of chronic rejection in animal transplant
odels (36).
This study has several limitations. The expression of Ang
I receptors at the mRNA level would not provide infor-
ation about protein receptor density, and the small
mount of cardiac biopsy precluded assessment of these
eceptors at the protein level. Finally, our results are based
n correlation and regression analyses, which do not estab-
ish a causal relationship between Ang II receptors and
CAD.
onclusions. To our knowledge, this is the first human
tudy demonstrating upregulation of AT1R in the donor
nd in the donor heart after transplantation in recipients
ho have developed transplant vasculopathy. We speculate
hat increased AT1R levels in the transplanted heart in
ecipients who prospectively developed TCAD may repre-
ent remnants of increased systemic and regional expression
f these receptors in the donor prior to transplantation.
ccordingly, the levels of AT1R mRNA in the donor
ymphocytes were correlated with those of the transplanted
eart and were identified as independent predictors for the
rogression of TCAD in recipients. The data would also
uggest that AT2R might play a role in transplant vascu-
opathy late after transplantation. These findings support a
ole for Ang II receptors in the pathogenesis of transplant
asculopathy. We hope that our data will prompt studies
imed at evaluating donor and recipient characteristics as a
ontinuum to elucidate the precise role of Ang II receptors
r other biological molecules in the pathogenesis of TCAD.
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